Treatment of hidradenitis suppurativa with etanercept injection

David Adams, Jessica A. Yankura, Anneli C. Fogelberg, Bryan Anderson

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objectives: To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. Design: Single-center, randomized, prospective, double-blind, placebo-controlled study. Setting: Academic dermatology practice. Patients: Twenty patients with active moderate to severe HS who fulfilled all inclusion criteria. Intervention: Etanercept, 50 mg, or placebo was administered subcutaneously (SC) twice weekly for 12 weeks. After 12 weeks, all patients received open-label etanercept, 50 mg, SC twice weekly for 12 more weeks. Main Outcome Measures: Primary end point: physician global assessment of HS as clear or mild at week 12. Secondary end points: patient global assessment and Dermatology Life Quality Index (DLQI). Results: There was no statistically significant difference among physician global assessment, patient global assessment, and DLQI at 12 or 24 weeks between treatment and placebo groups (P>.05 for all comparisons). Conclusions: Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS. In light of our negative results, as well as those of previous studies, we suggest that future studies focus on other agents for the treatment of HS. Trial Registration: clinicaltrials.gov Identifier: NCT00949546

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalArchives of dermatology
Volume146
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Hidradenitis Suppurativa
Injections
Dermatology
Skin Manifestations
Placebos
Physicians
Therapeutics
Quality of Life
Etanercept
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Adams, David ; Yankura, Jessica A. ; Fogelberg, Anneli C. ; Anderson, Bryan. / Treatment of hidradenitis suppurativa with etanercept injection. In: Archives of dermatology. 2010 ; Vol. 146, No. 5. pp. 501-504.
@article{c22440d0c2014ff7a10d33597b8120e5,
title = "Treatment of hidradenitis suppurativa with etanercept injection",
abstract = "Objectives: To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. Design: Single-center, randomized, prospective, double-blind, placebo-controlled study. Setting: Academic dermatology practice. Patients: Twenty patients with active moderate to severe HS who fulfilled all inclusion criteria. Intervention: Etanercept, 50 mg, or placebo was administered subcutaneously (SC) twice weekly for 12 weeks. After 12 weeks, all patients received open-label etanercept, 50 mg, SC twice weekly for 12 more weeks. Main Outcome Measures: Primary end point: physician global assessment of HS as clear or mild at week 12. Secondary end points: patient global assessment and Dermatology Life Quality Index (DLQI). Results: There was no statistically significant difference among physician global assessment, patient global assessment, and DLQI at 12 or 24 weeks between treatment and placebo groups (P>.05 for all comparisons). Conclusions: Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS. In light of our negative results, as well as those of previous studies, we suggest that future studies focus on other agents for the treatment of HS. Trial Registration: clinicaltrials.gov Identifier: NCT00949546",
author = "David Adams and Yankura, {Jessica A.} and Fogelberg, {Anneli C.} and Bryan Anderson",
year = "2010",
month = "5",
day = "1",
doi = "10.1001/archdermatol.2010.72",
language = "English (US)",
volume = "146",
pages = "501--504",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "5",

}

Treatment of hidradenitis suppurativa with etanercept injection. / Adams, David; Yankura, Jessica A.; Fogelberg, Anneli C.; Anderson, Bryan.

In: Archives of dermatology, Vol. 146, No. 5, 01.05.2010, p. 501-504.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of hidradenitis suppurativa with etanercept injection

AU - Adams, David

AU - Yankura, Jessica A.

AU - Fogelberg, Anneli C.

AU - Anderson, Bryan

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objectives: To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. Design: Single-center, randomized, prospective, double-blind, placebo-controlled study. Setting: Academic dermatology practice. Patients: Twenty patients with active moderate to severe HS who fulfilled all inclusion criteria. Intervention: Etanercept, 50 mg, or placebo was administered subcutaneously (SC) twice weekly for 12 weeks. After 12 weeks, all patients received open-label etanercept, 50 mg, SC twice weekly for 12 more weeks. Main Outcome Measures: Primary end point: physician global assessment of HS as clear or mild at week 12. Secondary end points: patient global assessment and Dermatology Life Quality Index (DLQI). Results: There was no statistically significant difference among physician global assessment, patient global assessment, and DLQI at 12 or 24 weeks between treatment and placebo groups (P>.05 for all comparisons). Conclusions: Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS. In light of our negative results, as well as those of previous studies, we suggest that future studies focus on other agents for the treatment of HS. Trial Registration: clinicaltrials.gov Identifier: NCT00949546

AB - Objectives: To observe the effects of etanercept treatment on the cutaneous manifestations of hidradenitis suppurative (HS) and to evaluate physician and patient global assessment scores of cutaneous manifestations. Design: Single-center, randomized, prospective, double-blind, placebo-controlled study. Setting: Academic dermatology practice. Patients: Twenty patients with active moderate to severe HS who fulfilled all inclusion criteria. Intervention: Etanercept, 50 mg, or placebo was administered subcutaneously (SC) twice weekly for 12 weeks. After 12 weeks, all patients received open-label etanercept, 50 mg, SC twice weekly for 12 more weeks. Main Outcome Measures: Primary end point: physician global assessment of HS as clear or mild at week 12. Secondary end points: patient global assessment and Dermatology Life Quality Index (DLQI). Results: There was no statistically significant difference among physician global assessment, patient global assessment, and DLQI at 12 or 24 weeks between treatment and placebo groups (P>.05 for all comparisons). Conclusions: Etanercept, 50 mg, SC administered twice weekly did not have significant efficacy in the improvement of HS. In light of our negative results, as well as those of previous studies, we suggest that future studies focus on other agents for the treatment of HS. Trial Registration: clinicaltrials.gov Identifier: NCT00949546

UR - http://www.scopus.com/inward/record.url?scp=77952643810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952643810&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2010.72

DO - 10.1001/archdermatol.2010.72

M3 - Article

VL - 146

SP - 501

EP - 504

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 5

ER -